| Title | Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study |
| Authors | Chen, Bowen Lei, Jin Zhao, Haitao Dong, Jinghui Zeng, Zhen Li, Yinyin Yu, Lingxiang Zhou, Lin Jia, Aiying Lu, Yinying Cheng, Jiamin |
| Affiliation | Fifth Med Ctr PLA Gen Hosp, Sr Dept Hepatol, Beijing, Peoples R China Peking Univ, Clin Med Sch 302, Beijing, Peoples R China Guizhou Med Univ, Clin Med Sch, Guiyang, Peoples R China Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Liver Surg, Beijing, Peoples R China Fifth Med Ctr PLA Gen Hosp, Radiol Dept, Beijing, Peoples R China Fifth Med Ctr PLA Gen Hosp, Dept Oncol, Beijing, Peoples R China Fifth Med Ctr PLA Gen Hosp, Sr Dept Hepatol, 100,Middle Rd West 4th Ring, Beijing 100039, Peoples R China |
| Keywords | UNRESECTABLE HEPATOCELLULAR-CARCINOMA IMMUNOTHERAPY LENVATINIB SORAFENIB OUTCOMES IMPACT OLDER |
| Issue Date | 2022 |
| Publisher | JOURNAL OF HEPATOCELLULAR CARCINOMA |
| Abstract | Purpose: To explore the efficacy and safety of sorafenib-or lenvatinib-based combination therapy with PD-1 inhibitors in elderly patients aged >75 years with unresectable hepatocellular carcinoma (uHCC).Patients and Methods: Systemic therapy-naive uHCC patients who received first-line sorafenib-or lenvatinib-based combination therapy with PD-1 inhibitors were continually reviewed. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) in accordance with the Response Evaluation Criteria in Solid Tumors version 1.1. Adverse events (AEs) and immune-related AEs (irAEs) were also evaluated. Groups and subgroups were separated at the ages of 65 and 75 years and compared with 1:1 matching.Results: Total 169 eligible patients were enrolled, including 24 aged >75 years. Median progression-free survival (PFS) and overall survival (OS) in these 24 elderly patients were 4.6 (95% CI: 2.6-6.6) months, and 17.0 (95% CI: 11.2-22.8) months, with 3-, 6-, 12 -month OS rate at 82.90%, 73.70%, and 57.50%. Age >75 years was confirmed to be a risk factor influencing PFS among patients aged >65 years. Adverse events (AEs) were recorded in all these 24 elderly patients, with seven patients experiencing immune-mediated AEs (irAEs). Nearly 30% of elderly patients stopped treatment due to AEs (16% of these due to irAEs). No statistical differences were found in all efficacy endpoints at the cutoff age of 65 years.Conclusion: For patients aged >75 years, application of PD-1 inhibitors in combination with sorafenib or lenvatinib is promising, but this has to be done with caution and needs to be confirmed by future prospective studies. |
| URI | http://hdl.handle.net/20.500.11897/658553 |
| DOI | 10.2147/JHC.S387254 |
| Indexed | SCI(E) |
| Appears in Collections: | 待认领 |
